Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyMedica site of service Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentMedicaPolicy N/A

    Site of Service program for infused specialty medications

    Customize your policy alerts

    Sign up for all Medica policy alerts

    Know when Medica releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Medica's Site of Service program directing members to the most cost-effective, clinically appropriate locations (e.g., home infusion or physician office) for select infused specialty medications and governs prior authorization and exceptions for applicable Commercial and Individual memberships.

    Policy Summary
    PayerMedica
    PolicySite of Service program for infused specialty medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2019
    Last ReviewMar 17, 2025
    Next Review Date
    Key ActionAll drugs in the Site of Service program require prior authorization submitted via gatewayPA.com (Providers).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2019-01-01program effective date

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60-90 days
    transition period
    Commercial, Individualmembership types
    J-/Q- listdrugs in scope
    MN, NDstate exemptions

    Site of Service Coverage Criteria

    Site of Service coverage criteria

    Covered with criteria and prior authorization; temporary medical necessity waivers available.

    All drugs listed in the Site of Service program require prior authorization and will be directed to a preferred alternative site of care (home infusion or physician office). Infusions administered in a hospital outpatient infusion center for these medications are excluded from payment unless an exception is approved.

    Temporary transition/waiver

    • Site of Service program requirements will be waived for 60-90 days to allow members beginning a new treatment or initial continuation review to transition to an alternate infusion site; this temporary approval is granted via the prior authorization process.

    Longer-term medical necessity exceptions (case-by-case)

    • Hospital outpatient administration may be considered medically necessary when potential changes in the member's clinical condition require immediate access to hospital services (e.g., need for emergency resuscitation equipment/personnel, potential for inpatient admission or intensive care).
    • History of anaphylaxis to prior infusion therapy with a related agent despite standard premedication.
    • Unstable or not intact vascular access that prevents safe administration outside the hospital.
    • Documented cardiopulmonary conditions or other clinical history that increase risk of severe adverse reactions (examples include thromboembolism, hypotension, seizures, aseptic meningitis syndrome, anaphylaxis, acute respiratory distress, pulmonary edema, apnea, transfusion-associated lung injury).
    • Lack of access to home infusion services and travel to the nearest office-based provider exceeds travel to the currently servicing hospital outpatient facility.
    • Age-based considerations (member is younger than 18 or older than 64) or other member-specific reasons documented by the provider (e.g., caregiver availability, exposure concerns) that justify hospital outpatient administration.
    Exceptions to the Site of Service program requirements are reviewed and granted on a case-by-case basis through the prior authorization process and require documentation of medical necessity or other supporting circumstances (for example: unsafe home environment, high financial impact, or age-based considerations).

    Infused Specialty Medication Codes in Scope

    Selected infused specialty medication J-/Q- codesHCPCSCovered
    J3262ACTEMRA / tocilizumab
    J1931ALDURAZYME / laronidase
    Q5121AVSOLA / infliximab-axxq
    J0490BENLYSTA / belimumab
    J0597BERINERT / C1 esterase inhibitor
    J1556BIVIGAM / intravenous immune globulin
    J2329BRIUMVI / ublituximab-xiiy
    J1745REMICADE / infliximab
    J1300SOLIRIS / eculizumab
    J2357XOLAIR / omalizumab

    Provider Requirements and Exceptions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all drugs in the Site of Service program. Submit prior authorization requests at gatewayPA.com — select Providers and use the Access Request - Provider workflow if this is your first time. To avoid delays in care, program requirements may be temporarily waived for a 60–90 day transition period following prior authorization approval to allow members to move to an alternate infusion site.

    • All Site of Service drugs require prior authorization
    • Submit requests at gatewayPA.com (Providers -> Access Request - Provider for first-time users)
    • Temporary waiver of site requirements for 60–90 days after prior authorization approval to permit transition
    Denial Risk

    Exceptions and Medical Necessity Review

    Exceptions to the Site of Service program are reviewed via prior authorization and may be granted on a case-by-case medical necessity basis. Hospital outpatient administration of infusion or injectable therapy is generally not considered medically necessary unless one of the following applies: a medically necessary 60–90 day period for members beginning a new treatment or at initial review of continuation of therapy; or documented clinical indications that require hospital-level services, emergency resuscitation capability, or immediate inpatient admission/ICU availability.

    Key Definitions

    Site of Service prior authorization
    Program requirementAll drugs in the Site of Service program require prior authorization and the program is administered as part of the existing prior authorization program.
    Submission methodPrior authorization requests must be submitted via gatewayPA.com (select 'Providers').
    Payment exclusionInfusions of listed specialty medications administered in a hospital outpatient infusion center are excluded from payment unless an exception is approved.
    Preferred alternative sitesRequests for select specialty drugs to be administered in a hospital outpatient setting will be directed to preferred alternative sites such as home infusion providers or physician offices.
    Transition waiver periodTo prevent delay in care, Site of Service requirements may be waived for 60-90 days to allow members to transition to an alternate infusion site after prior authorization approval.
    Policy Summary
    PayerMedica
    PolicySite of Service program for infused specialty medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2019
    Last ReviewMar 17, 2025
    Next Review Date
    Key ActionAll drugs in the Site of Service program require prior authorization submitted via gatewayPA.com (Providers).
    SourceLink
    On This Page
    Site of Service Coverage CriteriaInfused Specialty Medication Codes in ScopeProvider Requirements and ExceptionsKey Definitions
    • Exceptions reviewed through prior authorization on a case-by-case medical necessity basis
    • Hospital outpatient administration may be authorized for up to 60–90 days for new treatment starts or initial continuation review
    • Hospital outpatient administration may be authorized when there is risk of sudden life‑threatening change requiring hospital services (examples include: intolerable fluid overload or unstable renal function; acute mental status/cognitive changes or physical impairment with no home caregiver; history of anaphylaxis to prior infusion despite premedication; unstable vascular access; documented cardiopulmonary conditions that increase risk of severe adverse reactions)
    • Authorization may be considered when the member lacks access to home infusion and the nearest office-based provider exceeds travel distance to the current hospital outpatient site
    • Age-based considerations may apply (e.g., members <18 or >64) and other individual member circumstances may be considered during review
    Medical necessity (hospital outpatient infusion)
    General ruleHospital outpatient administration of infusion or injectable therapy is not considered medically necessary for listed medications unless specified criteria are met and prior authorization grants an exception.
    Temporary medical necessityHospital outpatient administration may be considered medically necessary for up to 60-90 days for members beginning a new treatment or during initial continuation review to allow transition.
    Immediate-access clinical risksLonger-term hospital outpatient administration may be considered medically necessary when immediate access to hospital services is required (e.g., significant risk of sudden life‑threatening changes, need for emergency resuscitation and inpatient admission capabilities).
    Specific clinical risk factorsExamples of clinical risk factors supporting medical necessity include intolerable fluid overload or unstable renal function, history of anaphylaxis to related agents despite premedication, unstable vascular access, and documented cardiopulmonary conditions increasing risk of severe adverse reactions.
    Access and age considerationsMedical necessity may also be supported when the member lacks access to home infusion or nearest office exceeds travel distance, or based on age criteria (younger than 18 or older than 64).